Alligator Bioscience AB (publ) (STO: ATORX)
Sweden
· Delayed Price · Currency is SEK 0.503
-0.076 (-13.13%)
Nov 20, 2024, 5:29 PM CET
Alligator Bioscience AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 27.73 | 58.11 | 35.7 | 12.94 | 4.35 | 4.36 | Upgrade
|
| Other Revenue | 0.05 | 1.14 | 0.31 | 0.38 | 1.16 | - | Upgrade
|
| Revenue | 27.77 | 59.25 | 36 | 13.33 | 5.52 | 4.36 | Upgrade
|
| Revenue Growth (YoY) | -58.88% | 64.58% | 170.14% | 141.65% | 26.55% | -83.88% | Upgrade
|
| Cost of Revenue | 182.11 | 218.79 | 147.73 | 86.98 | 82.32 | 145.38 | Upgrade
|
| Gross Profit | -154.34 | -159.54 | -111.72 | -73.66 | -76.81 | -141.02 | Upgrade
|
| Selling, General & Admin | 77.31 | 79.38 | 68.84 | 56.85 | 55.71 | 60.61 | Upgrade
|
| Other Operating Expenses | -1.27 | -0.02 | -0.03 | -0 | -0 | -0 | Upgrade
|
| Operating Expenses | 85.62 | 89.85 | 80.58 | 68 | 67.23 | 72.15 | Upgrade
|
| Operating Income | -239.96 | -249.39 | -192.3 | -141.65 | -144.04 | -213.17 | Upgrade
|
| Interest Expense | -10.44 | -0.48 | -0.65 | -0.23 | -0.31 | -0.42 | Upgrade
|
| Interest & Investment Income | 2.58 | 1.88 | - | - | 0.19 | 1.26 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.49 | -0.6 | -0.46 | -0.14 | -0.6 | 0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | 0 | 0 | - | -0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -248.31 | -248.59 | -193.41 | -142.03 | -144.75 | -212.24 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 1.46 | 2.13 | Upgrade
|
| Other Unusual Items | - | - | - | -0.96 | - | - | Upgrade
|
| Pretax Income | -248.31 | -248.59 | -193.4 | -141.74 | -143.3 | -210.11 | Upgrade
|
| Net Income | -248.31 | -248.59 | -193.4 | -141.74 | -143.3 | -210.11 | Upgrade
|
| Net Income to Common | -248.31 | -248.59 | -193.4 | -141.74 | -143.3 | -210.11 | Upgrade
|
| Shares Outstanding (Basic) | 693 | 448 | 221 | 90 | 71 | 71 | Upgrade
|
| Shares Outstanding (Diluted) | 693 | 448 | 221 | 90 | 71 | 71 | Upgrade
|
| Shares Change (YoY) | 95.35% | 103.32% | 146.00% | 25.61% | - | - | Upgrade
|
| EPS (Basic) | -0.36 | -0.55 | -0.88 | -1.58 | -2.01 | -2.94 | Upgrade
|
| EPS (Diluted) | -0.36 | -0.55 | -0.88 | -1.58 | -2.01 | -2.94 | Upgrade
|
| Free Cash Flow | -233.19 | -191.74 | -173.05 | -127.08 | -141.45 | -183.16 | Upgrade
|
| Free Cash Flow Per Share | -0.34 | -0.43 | -0.78 | -1.42 | -1.98 | -2.57 | Upgrade
|
| Gross Margin | - | -269.26% | - | - | - | - | Upgrade
|
| Operating Margin | -863.96% | -420.90% | -534.16% | -1062.89% | -2611.71% | -4891.49% | Upgrade
|
| Profit Margin | -894.02% | -419.55% | -537.22% | -1063.53% | -2598.30% | -4821.29% | Upgrade
|
| Free Cash Flow Margin | -839.61% | -323.61% | -480.67% | -953.54% | -2564.90% | -4202.80% | Upgrade
|
| EBITDA | -239.72 | -248.24 | -188.89 | -136.7 | -138.51 | -207.47 | Upgrade
|
| D&A For EBITDA | 0.24 | 1.15 | 3.41 | 4.95 | 5.53 | 5.7 | Upgrade
|
| EBIT | -239.96 | -249.39 | -192.3 | -141.65 | -144.04 | -213.17 | Upgrade
|
| Revenue as Reported | 30.56 | 61.9 | 37.14 | 15.13 | 6.67 | 5.4 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.